Genentech Reports Positive Results of Rituxan (rituximab) in P-III PEMPHIX Study to Treat Patients with Moderate to Severe Pemphigus Vulgaris
Shots:
- The P-III PEMPHIX Study (NCT02383589) involves assessing of Rituxan (1000mg- IV) vs mycophenolate mofetil (MMF) in patients with moderate to severe active pemphigus vulgaris
- The P-III PEMPHIX study met its 1EPs & 2EPs and further demonstrated superior results to MMF in regards to sustained complete remission
- Rituxan (rituximab) is a mAb used to target cancer cells with CD20 marker and is a novel therapy approved by the US FDA in June 2018 for pemphigus vulgaris on basis of Ritux 3 clinical trial
Ref: Genentech | Image: Fortune
Click here to read the full press release
Tags
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com